SPX-104 / SparX - LARVOL DELTA

Discovery and characterization of LILRB2XPD-L1 bispecific antibody SPX-303 (AACR 2024) - "In in vitro functional assays, SPX-303 exhibits effects comparable to the parental monomeric anti-LILRB2 (SPX-104) in redirecting macrophage polarization from M2 to M1 stage, as observed in both cultured PBMC and human monocyte-derived macrophage (HMDM) models. Collectively, these results support SPX-303 as a novel therapeutic antibody that effectively enhances anti-cancer immunity in the treatment of advanced solid tumors. The pre-clinical data as well as the clinical plan of SPX-303 will be presented."

Oncology • Solid Tumor

Discovery and characterization of anti-LILRB2 antibody SPX-104 (AACR 2023) - "These results confirm enhanced T cell activity following macrophage redirected polarization. The in vitro and in vivo evaluation, of SPX-104 relative to other anti-LILRB2 antibodies will be presented."

IO biomarker • Oncology • CD34 • IFNG • TNFA